Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek ...

Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma. Design: Multicentre ...

Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance ...

Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where OptiNose Inc. (NASDAQ:OPTN) ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...

The active ingredient of Xhance is fluticasone propionate. It’s available as the generic drug fluticasone propionate nasal spray. A generic drug is considered to be as safe and effective as the ...

Fluticasone propionate 44mcg/inh, 110mcg/inh, 220mcg/inh; metered dose inhaler; CFC-free. Flovent HFA is supplied in the following boxes of 1 as a pressurized aluminum canister fitted with a ...

Fluticasone propionate, salmeterol (as xinafoate); 45mcg/21mcg, 115mcg/21mcg, 230mcg/21mcg; per inh; metered-dose inhaler; CFC-free. Store at room temperature between 68° F and 77° F (20° C and ...

Objective: To compare the efficacy and tolerability of a salmeterol/fluticasone propionate (FP) combination product (50/100µg twice daily) with budesonide (BUD) at a four-fold higher microgram ...

including its approved product XHANCE (fluticasone propionate). After the transaction, OPTN shareholders will expect to receive $14 for each share, including the payment of contingent value ...